Rezolute, Inc. RZLT

RZLT Company Overview

Rezolute, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare metabolic and endocrine diseases. The company’s primary focus has been the development of treatments for conditions associated with dysregulated insulin activity, particularly congenital hyperinsulinism (CHI), a rare pediatric disease characterized by excessive insulin production that can cause severe hypoglycemia. Rezolute operates within the biotechnology and rare disease pharmaceutical industries, with its business model centered on clinical development, regulatory advancement, and potential commercialization of novel biologic therapies.

The company’s lead product candidate has been ersodetug (RZ358), a monoclonal antibody designed to modulate insulin receptor signaling and reduce persistent hypoglycemia in patients with CHI. Rezolute has positioned itself within the orphan drug and rare disease segment, where smaller patient populations may benefit from accelerated regulatory pathways, orphan drug exclusivity, and specialized clinical expertise. Originally formed through a series of biotechnology asset acquisitions and restructurings, the company evolved from earlier metabolic disease programs into a more focused rare disease development strategy emphasizing endocrine disorders with high unmet medical need.